AN 845
Alternative Names: AN-845Latest Information Update: 21 Dec 2021
Price :
$50 *
At a glance
- Originator Acura NanoMedicine
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Preclinical Cancer; Glioblastoma; Liver cancer; Pancreatic cancer
Most Recent Events
- 13 Dec 2021 AN 845 is available for licensing as of 13 Dec 2021. https://www.acura-nanomed.com/ 9344972
- 13 Dec 2021 Preclinical trials in Cancer in Taiwan (Intratumoural) (Acura Nanomedicine pipeline, December 2021)
- 13 Dec 2021 Preclinical trials in Cancer in Taiwan (IV) (Acura Nanomedicine pipeline, December 2021)